Palatin Technologies Future Growth

Future criteria checks 2/6

Palatin Technologies is forecast to grow earnings and revenue by 64.9% and 55.1% per annum respectively while EPS is expected to grow by 67.7% per annum.

Key information

64.9%

Earnings growth rate

67.7%

EPS growth rate

Biotechs earnings growth	21.2%
Revenue growth rate	55.1%
Future return on equity	n/a
Analyst coverage	Low
Last updated	08 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NYSEAM:PTN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	43	-12	N/A	N/A	2
6/30/2025	7	-21	N/A	-27	2
6/30/2024	4	-27	N/A	-30	3
12/31/2023	7	-35	-17	-27	N/A
9/30/2023	6	-25	-26	-26	N/A
6/30/2023	5	-28	-29	-28	N/A
3/31/2023	4	-25	-28	-27	N/A
12/31/2022	3	-26	-36	-35	N/A
9/30/2022	2	-37	-32	-32	N/A
6/30/2022	1	-36	-30	-30	N/A
3/31/2022	1	-37	-31	-31	N/A
12/31/2021	1	-35	-25	-25	N/A
9/30/2021	0	-37	-33	-33	N/A
6/30/2021	0	-34	-23	-23	N/A
3/31/2021	0	-27	-20	-20	N/A
12/31/2020	0	-27	-19	-19	N/A
9/30/2020	0	-22	-10	-10	N/A
6/30/2020	0	-22	41	41	N/A
3/31/2020	60	37	40	40	N/A
12/31/2019	60	37	39	39	N/A
9/30/2019	60	37	38	39	N/A
6/30/2019	60	36	-22	-22	N/A
3/31/2019	21	-5	-4	-4	N/A
12/31/2018	30	0	-8	-8	N/A
9/30/2018	40	8	-5	-5	N/A
6/30/2018	67	25	2	2	N/A
3/31/2018	80	26	-22	-22	N/A
12/31/2017	82	23	29	29	N/A
9/30/2017	72	10	N/A	21	N/A
6/30/2017	45	-13	N/A	13	N/A
3/31/2017	11	-40	N/A	12	N/A
12/31/2016	N/A	-49	N/A	-42	N/A
9/30/2016	N/A	-52	N/A	-45	N/A
6/30/2016	N/A	-52	N/A	-47	N/A
3/31/2016	N/A	-50	N/A	-43	N/A
12/31/2015	N/A	-47	N/A	-38	N/A
9/30/2015	8	-31	N/A	-28	N/A
6/30/2015	13	-18	N/A	-13	N/A
3/31/2015	13	-10	N/A	-8	N/A
12/31/2014	13	-2	N/A	-5	N/A
9/30/2014	5	-9	N/A	-4	N/A
6/30/2014	N/A	-14	N/A	-12	N/A
3/31/2014	N/A	-14	N/A	-13	N/A
12/31/2013	N/A	-17	N/A	-15	N/A
9/30/2013	0	-15	N/A	-11	N/A
6/30/2013	0	-21	N/A	-14	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PTN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PTN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PTN's revenue (55.1% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: PTN's revenue (55.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PTN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Palatin Technologies Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 73% to US$11.50

Consensus revenue estimates fall by 65%

Consensus revenue estimates fall by 65%

No longer forecast to breakeven

Price target increased by 40% to US$60.00

Forecast to breakeven in 2026

Recent updates

Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease (Ded) Clinical Data Results Presented At American Society of Cataract and Refractive Surgery (Ascrs) 2024

Price target decreased by 73% to US$11.50

Consensus revenue estimates fall by 65%

Consensus revenue estimates fall by 65%

No longer forecast to breakeven

Price target increased by 40% to US$60.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

New major risk - Shareholder dilution

Palatin Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $10.000006 million.

New major risk - Share price stability

Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024

Forecast to breakeven in 2026

Consensus EPS estimates fall by 12%

Palatin Technologies Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$1.29 loss

Palatin Technologies, Inc. to Report Q1, 2024 Results on Nov 14, 2023

Palatin Technologies, Inc. announced that it expects to receive $5.000001 million in funding

New major risk - Share price stability

Palatin Technoloes, Inc. Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin Receives Notice of Non-Compliance from NYSE American

Consensus revenue estimates increase by 28%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Palatin Technologies, Inc. to Report Q4, 2023 Results on Sep 28, 2023

Palatin Technologies, Inc. Completes Enrollment in Phase 3 Melody-1 Study of PL9643 for the Treatment of Patients with Dry Eye Disease

Palatin Technologies, Inc. Initiates Clinical Program for Bremelanotide Co-Formulated with A Pde5i for the Treatment of Ed in Patients Non-Responsive to Pde5i Treatment

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

New minor risk - Share price stability

Consensus revenue estimates fall by 24%

Palatin Technologies, Inc., Annual General Meeting, Jun 20, 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Palatin Technologies, Inc. to Report Q3, 2023 Results on May 16, 2023

Palatin Technologies, Inc. Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

Consensus revenue estimates decrease by 42%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Palatin Technologies, Inc. to Report Q2, 2023 Results on Feb 15, 2023

Palatin Technologies Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions

Consensus revenue estimates increase by 72%

Price target decreased to US$43.00

Insufficient new directors

Palatin Technologies, Inc. to Report Q1, 2023 Results on Nov 14, 2022

Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $9.999921 million.

Palatin Technologies, Inc. Announces First Patient Has Been Enrolled in the Pl8177-205 Study with Palatin's Pl8177

Consensus forecasts updated

Consensus forecasts updated

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Palatin Technologies, Inc. to Report Q4, 2022 Results on Sep 22, 2022

Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis

Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease

Palatin Technologies, Inc. Announces Appointment of Carl Spana as Chief Executive Officer Effective July 1, 2022

Palatin Technologies, Inc., Annual General Meeting, Jun 24, 2022

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Palatin Technologies, Inc. to Report Q3, 2022 Results on May 17, 2022

Price target increased to US$3.33

Insufficient new directors

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Palatin Technologies, Inc. to Report Q2, 2022 Results on Feb 15, 2022

Palatin Technologies, Inc. Announces Initiation of Pivotal Phase 3 Pl9643 Melody-1 Clinical Trial in Patients with Dry Eye Disease

First quarter 2022 earnings released: US$0.03 loss per share (vs US$0.017 loss in 1Q 2021)

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.096 loss in FY 2020)

Palatin Technologies, Inc. Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

Palatin Technologies, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease

Consensus forecasts updated